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ABSTRACT
Purpose/Objectives: Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival of less than 4 months
(m). This study evaluated the efficacy of fractionated stereotactic re-irradiation (FSRT)
for patients with HGG after progression on Bevacizumab.
Materials/Methods: Retrospective review was conducted of patients treated with
FSRT after progression on bevacizumab. A total of 36 patients were identified. FSRT
was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival
from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as
study endpoints. Univariate and multivariate analysis was performed.
Results: Among the 36 patients, 31 patients had recurrent glioblastoma, and 5 patients
had recurrent anaplastic astrocytoma. The median time from initial bevacizumab
treatment to FSRT was 8.5 m (range 2.3 – 32.0 m). The median plan target volume for
FSRT was 27.5 cc (range 1.95 – 165 cc). With a median follow up of 20.4 m, the overall
survival of the patients since initial diagnosis was also 24.9 m. The median overall
survival after initiation of bevacizumab was 13.4 months. The median overall survival
from FSRT was 4.8 m. FSRT treatment was well tolerated with no Grade >3 toxicity.
Conclusions: Favorable outcomes were observed in patients with recurrent HGG
who received salvage FSRT after bevacizumab failure. The treatment was well
tolerated. Prospective study is warranted to further evaluate the efficacy of salvage
FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed
bevacizumab treatment.
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INTRODUCTION
Malignant gliomas are the most common
brain tumors, with an estimated yearly
incidence of 3 per 100,000 people in the
United States.1 Despite multiple modalities for definitive therapy (which include
resection, radiation therapy (RT) and
chemotherapy), these lesions have an
unfortunately high rate of recurrence. 2
Therefore, even despite recent treatment advances in targeted therapies
for glioblastoma (GBM) and high grade
glioma (HGG) such as bevacizumab, the
long-term outcomes for these patients
remain poor.
In modern clinical practice, treatment
failure of recurrent HGGs largely represents failure of bevacizumab therapy.3
In addition to disease recurrence itself
driving poor outcomes, there is evidence
that these patients who fail bevacizumab
also harbor disease that is resistant to
other systemic therapies.4 Therefore,
treatment options for these recurrent
patients remain limited and their prognosis is dismal with a recent review of
sixteen studies reporting an overall
survival (OS) of under 4 months after
bevacizumab failure.4-6
Multiple modalities of radiotherapy have
been investigated for this population,
including stereotactic radiosurgery (SRS)
and brachytherapy. These interventions
have been shown to have modest utility,
but with the potential for significant
associated toxicity. In that context, fractionated stereotactic radiotherapy (FSRT)
is a promising treatment modality for the
treatment of these refractory HGGs. This
modality possesses the precise targeting
advantages of SRS but with the dosesparing radiobiologic properties of
fractionation to allow greater sparing
of surrounding critical structures, thus
limiting toxicity. 7,8 Taken together,
FSRT therefore possesses the potential
for decreased toxicity as compared to
SRS while still providing excellent local
control.9 The present study sought
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to evaluate the safety and efficacy of
FSRT in patients who failed therapy with
bevacizumab.

Table 1. Patient Demographic and Treatment Information. Descriptive data on our study cohort is
shown, encompassing demographic data, clinical information and treatment information.
Number of patients

MATERIALS AND METHODS
Patients
The Thomas Jefferson University institutional review board approved this
single-institution, retrospective study.
Patients who received FSRT salvage
after progression on bevacizumab were
included. A total of 36 patients were identified from 2006 to 2013. Patients who
received FSRT within 2 months of initiation
of bevacizumab were excluded. Patients
were followed with MRI scans and clinical
assessment, which were obtained 6 to 8
weeks after FSRT and at approximately
2-month intervals thereafter.

36

Gender
Male

17

Female

19

Median Age at FSRT salvage (range)

56 years (37-73)

Median KPS at FSRT salvage (range)

80 (50-100)

Histology at Recurrence
GBM

30

Anaplastic glioma

4 (3-4)

Other

2 (1-2)

Median Volume of Recurrence (range)

27.5 cc (1.95-165)

Median Radiation Dose (range)

35 Gy (30-37.5)

Median time from Bev to FSRT (range)

(2.4-32.1)

Treatment Planning
Treatment decisions were based on
consensus recommendations following
discussion in our institution’s multidisciplinary brain tumor board consisting of
radiologists, neurosurgeons, neuro-oncologists, neuropathologists and radiation
oncologists. Prior to 2004, treatment planning was conducted with the X-knife 3-D
planning system (Radionics, Burlington,
MA, USA), which delivered 6 MV photons
with a dedicated stereotactic 600SR linear
accelerator (Varian, Palo Alto, CA, USA).
From 2004 to 2013, treatment planning
was carried out with Brain Lab (Novalis)
using mMLC leaves with a leave thickness
of 3 mm and Exac Trac on board imaging.
All patients undergoing irradiation were
fitted with custom-made Brainlab (Munich,
Germany) thermal plastic masks for
immobilization. Treatment planning MRI
and computed tomography (CT) images
were obtained and fused. All patients had
thin cut (1-1.5 mm) fat suppressed coronal
post-contrast MRI. The gross tumor
volume (GTV) was defined on MRI using
the gadolinium enhanced T1 weighted
series, as peripherally enhancing tissue.
Surrounding edema was not purposely
included in the treatment volume. The
planning target volume was the GTV with
minimum margin (0-2 mm per the treating
physician). Critical normal structures, such
as optic nerves, chiasm, and brainstem
were also contoured. Treatment planning was carried out with Brain Lab Iplan
(Munich, Germany). The radiation planning used dynamic conformal arcs, IMRT
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(intensity modulated radiation therapy) or
hybrid-Arcs (Brainlab, Munich, Germany),
a combination of dynamic arcs with IMRT
beams. The patients were treated with
FSRT to a median PTV dose of 35 Gy
delivered in 3.5 Gy fractions.10 The dose
was reduced to 30 Gy in 3 Gy fractions
for large targets, and high critical normal
structure dose. The constraints for normal
critical structures include: brainstem max
dose <20 Gy; optic nerve max dose < 15
Gy, chiasm max dose < 15 Gy.

Statistical analysis
The primary end point of the study was
overall survival from initial diagnosis, as
well as survival from first recurrence and
re-irradiation (described in greater detail
under Statistical Analyses). Toxicity was
also graded using Radiation Therapy
Oncology Group (RTOG) criteria. Overall
survival was defined as the time from
initial diagnosis to the time of death. Date
of recurrence was defined as the date of
radiographic evidence of progression.
Survival from recurrence and from reirradiation were therefore defined as the
time from this radiologic evidence or
radiation therapy until death, respectively.
Kaplan–Meier curves were generated for
the overall survival endpoint. Cox proportional hazard modeling was used for
multivariate analysis with factors analyzed
in a step-wise fashion. All statistical analysis was performed using the STATA data
analysis and statistical software version
13.1 (STATA Corporation).

RESULTS
Patient Population and Treatment
Parameters
We identified 36 patients with either
anaplastic astrocytoma (5 patients) or
glioblastoma multiforme (GBM) (30
patients) who had clinical and radiographic evidence of tumor progression on
bevacizumab and received FSRT between
2006 and 2013 (Table 1). One patient
had gemistocytic astrocytoma. Patient
characteristics are listed in Table 1. There
were 17 males and 19 females. All patients
received initial surgery and were treated
with radiation and temozolomide. The
median age at recurrence was 57.1 years
(range 37-73). The median Karnofsky
Performance Status at recurrence was
80%. Following disease progression on
bevacizumab, the median target volume
treated with FSRT was 27.5 cc (range
1.95 – 165 cc). The median dose was
35 Gy (range, 30 Gy – 37.5 Gy).

Survival
Patients underwent routine surveillance
for a median follow up of 20.4 m after
initial diagnosis, with an overall survival
from initial diagnosis of 24.9 m. Upon
evidence of initial disease recurrence,
patients were promptly started on bevacizumab. The median overall survival
after initiation of bevacizumab was 13.4
months. The median time from initial
bevacizumab treatment to initiation of
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Table 2. Survival Statistics. Survival data accrued from the study cohort is shown, expressed as
OS from diagnosis, recurrence and from FSRT.
Median Overall Survival (Range)
From Diagnosis

24.9 months (11.4-94.2)

From First Recurrence

12.0 months (4.2-49.1)

From FSRT

4.8 months (0.5-23.4)

Overall Survival

Prior to FDA-approval of bevacizumab,
FSRT had been previously studied in the
setting of recurrent HGG, with generally
favorable results. Multiple studies have
shown FSRT to be efficacious, with OS in
these studies ranging from 5-11 months.
Moreover, these studies showed FSRT to
be very well tolerated, with a low rate of
grade 3 toxicities, radiation necrosis (RN)
and reoperation.10-12

Percent survival

100
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0

0

20

40

60

80

100

Time (Months)

Figure 1. Kaplan-Meyer Overall Survival Curve.
Graph displays OS from the time diagnosis for patients who went on to fail bevacizumab
therapy and require FSRT in our study cohort.
salvage FSRT was 8.5 m (range 2.4 – 32 m),
and the median overall survival after FSRT
was 4.8 m. Data are presented in table form
(Table 2) as well as in the form of a KaplanMeyer survival curve (Figure 1).

p=0.04). Additionally, there was a trend
towards significance for re-resection
status associated with OS from FSRT (HR
1.87 p=0.17).

Multivariate Analysis

No patients demonstrated clinically
significant acute morbidity, with no grade
III or higher toxicity observed. All patients
were able to complete the prescribed
radiation course without interruption.
There were no observed hospitalizations
or surgeries for early acute or delayed
toxicity in the study population.

Multivariate analysis was performed to
investigate whether different variables
in our study population influenced OS
from recurrence or from FSRT therapy
(Table 3). These included age at recurrence, KPS score, volume of recurrence,
histology (AA vs GBM) or re-resection
status. Importantly, out of all of these
variables, only re-resection demonstrated
a statistically significant association with
overall survival from recurrence (HR 2.59;
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in patients with high-grade gliomas,
treatment failure and disease progression while on bevacizumab remain as
an unfortunate reality in managing these
patients. Therefore, overall prognosis
remains quite poor. Despite this clinical
need, there remains a paucity of literature
regarding the management of patients
who fail bevacizumab. In that context,
the present study investigated FSRT as a
potential treatment modality to address
this problem.

Toxicity

DISCUSSION
Despite recent advances such as bevacizumab that have extended overall survival

Of note, one study (Lederman et al.)
observed significantly more toxicity and
reoperation (11 of 88 patients) than the
others. This toxicity outlier can perhaps
be explained by the use of a different
dosing regimen (24 Gy in 4 fractions in
Lederman et al. versus 30-35 Gy in 6-10
fractions in the other studies).13 In a head
to head trial, Patel et al. compared stereotactic radiosurgery (SRS) with FSRT and
showed comparable overall survival and
radiographic tumor response between
the two modalities, with a trend towards
fewer events of radiation necrosis (RN) in
the FSRT cohort.14
The data on FSRT treatment following
bevacizumab failure is much more
limited. In a retrospective study, Torcuator et al. looked at two cohorts of
patients who failed bevacizumab: one
that received either FSRT or SRS and one
that received no FSRT/SRS. They demonstrated an increased overall survival in
patients receiving FSRT/SRS (7.2 vs 3.3
months in untreated patients). Another
study that is published only in abstract
form by Nehaw et al. similarly looked at
RT (including 6 patients who received
FSRT) versus non-RT regimens following
bevacizumab failure and showed statistically significant increased survival in the
radiation group (8.8 vs. 5.4 months for
untreated). Despite this small body of
literature, neither of these studies investigated FSRT alone after bevacizumab
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Table 3. Multivariate Analysis. Multivariate analysis is shown for the study cohort. Variables
were tested for association with OS from Recurrence as well as OS From FSRT. Data are
expressed as Hazard Ratios (HR) and p-value. P-value of <0.05 was considered significant.
OS from Recurrence Multivariate
Age at Recurrence

HR=0.99; p=0.67

KPS <=80

HR=1.27; p=0.61

Volume of recurrence >50cc

HR=1.09; p=0.32

Re-resection yes vs no

HR=2.59; p=0.04

Histology AA vs GBM

HR=0.99; p=0.99

OS from FSRT Multivariate
Age at Recurrence

HR=1.01; p=0.70

KPS <=80

HR=0.73; p=0.53

Volume of recurrence

>50cc HR=1.02; p=0.83

Re-resection yes vs no

HR=1.87; p=0.17

Histology AA vs GBM

HR=1.72; p=0.46

failure, nor did they report on safety or
toxicity of these approaches.
In that context, the present study
represents one of the first studies
to specifically investigate the role of
FSRT in the context of bevacizumab
failure. Indeed, our work builds off of
previous work by both our group and
others showing comparable benefit and
improved safety in FSRT regimens for
HGGs as compared to SRS for treatment
of HGG in other contexts.10,11,13 Specifically, the present study demonstrates
the feasibility, efficacy and tolerability
of such an approach in patients who fail
bevacizumab.
One limitation of our study is the lack of
a control cohort for comparison in terms
of outcomes to put our overall survival
into context. Historically, patients who
fail bevacizumab have been shown in a
recent review of sixteen studies to have
an overall survival of 3.8 months.4-6
Thus, our observed overall survival
compares favorably to, and indeed
exceeds that mark. Taken in the context
of the aforementioned studies which
show benefit of RT vs. no RT in bevacizumab failure, and also that FSRT and SRS
provide similar OS in recurrent gliomas
before bevacizumab treatment, our data
are consistent with these previous studies
and moreover suggest a role for FSRT in
the management of patients who fail
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bevacizumab. Despite our findings, it is
worth noting that one limitation of our
study is the potential bias of our dataset
in that it only includes patients who are
amenable to therapy with FSRT. Therefore it is difficult to directly compare our
survival data to the existing literature,
given that the literature includes all
patients, whether or not they are eligible
for FSRT. Further head-to-head studies
will be needed to evaluate FSRT versus
other modalities to definitively establish
a role and identify populations that would
most benefit.
Notably, our multivariate analysis yielded
only one variable that was associated with overall survival: re-resection
status. Indeed, there is controversy in
the literature regarding the prognostic
value of re-resection in patients with
recurrent HGG,2 but our data suggest
that re-resection is actually deleterious
in terms of survival outcomes. However,
given the retrospective nature of the
current study, it is difficult to draw strong
conclusions from these data, as re-resection status itself may be confounding by
representing underlying patient characteristics that lead to poorer prognosis.
Future studies will be needed to identify
patient populations who will most benefit
from an FSRT regimen.
Other limits to our study include a small
patient cohort (36) as well as those shortcomings inherent to all retrospective

studies including selection bias and
potential treatment differences in a
non-randomized study. Despite these
potential drawbacks, this study represents, to our knowledge, the largest
literature cohort of FSRT patients in the
context of bevacizumab failure. Moreover, the dire prognosis of these patients
and the paucity of data regarding their
management underscores the relevance
of the present study, and suggests the
need for future prospective randomized
trials to improve survival and positively
impact the lives of patients with HGG.

CONCLUSIONS
Favorable outcomes were observed using
FSRT to treat patients with recurrent HGG
and the treatment was well tolerated.
Prospective study is warranted to further
evaluate the efficacy of salvage FSRT for
patients with recurrent HGG after bevacizumab failure.
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